In November 2014, the US Food and Drug Administration (FDA) issued a black box warning against the use of power morcellation for excision of uterine fibroids to decrease the risk of disseminating malignant cells and worsening survival outcomes of patients with unexpected malignant neoplasms. After the FDA statement was issued, studies showed decreased rates of minimally invasive surgery and increased rates of open abdominal hysterectomy. However, there are limited and controversial data on the association of these changed rates with 30-day hysterectomy complications.
its use for "peri-and post-menopausal" women and for patients with "suspected or known malignancy."
Following the issue of the FDA warning, many institutions discouraged the use of any morcellation and banned the use of the power morcellator; there was a subsequent decrease in the use of power morcellation during surgical procedures among women who underwent a minimally invasive hysterectomy from 13.7% in early 2013 to 2.8% in early 2015. 13 Moreover, the results of 2 surveys of gynecologists evaluating the influence of the FDA warning on management strategies in hysterectomy and myomectomy showed that a large proportion of respondents shifted from the use of MIS to the use of a larger incision or open abdominal procedures, raising concerns about an increase of surgical complications.
14,15 Furthermore, the FDA decision was criticized for overestimating the risk associated with using power morcellation compared with the risk associated with preventing its use in a large group of women who could receive benefits from morcellation. 16 However, evaluating the contribution of the FDA statement to complications of hysterectomy to date has provided controversial results.
13, [17] [18] [19] Most importantly from a patient perspective, a survey distributed to more than 300 women in gynecologic waiting rooms regarding the consequence of limiting access to MIS and limiting women's choices indicated that at the 1 in 350 risk of a malignant tumor reported by the FDA, the majority of women would still choose an MIS approach. 20 The present study used the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) database to overcome the limitations of previous studies because data on complications up to 30 days after the index surgery are collected. We evaluated 30-day major and minor complications associated with hysterectomy before and after the FDA issued the warning statement about the use of power morcellators.
Methods

Database
Details about sampling methods, data abstraction procedures, variables, and outcomes collected by the ACS NSQIP database are described elsewhere. 21 In brief, the ACS NSQIP database is a prospective, validated, multicenter, clinical data registry designed to facilitate, measure, and enhance the quality of surgical care by providing hospitals with detailed reports of their risk-adjusted outcomes. The Mayo Clinic institutional review board deemed this study exempt from requiring approval because the data were deidentified. Data on more than 150 variables, including demographic characteristics, preoperative risk factors, laboratory test results, operative details, and postoperative outcomes up to 30 days after the index operation are collected from 603 participating academic and nonacademic hospitals. Data collection is performed directly from the medical record by trained data abstractors at each participating hospital, with regular onsite audits aimed to ensure data reliability.
Study Population
The analysis was restricted to patients who underwent hysterectomy for a benign gynecologic indication. Current Procedural Terminology codes were used to identify patients who underwent hysterectomy. Indications for hysterectomy were identified using the International Classification of Diseases, Ninth and Tenth Revision diagnosis codes. We excluded patients with associated procedures indicating the presence of malignant neoplasms or those who underwent hysterectomy with an indication of malignant neoplasm or uncertain behavioral diseases, as well as patients who underwent a pregnancy-related hysterectomy or an emergent hysterectomy, in which emergent was identified as patients with American Society of Anesthesiologists class 5; ventilator dependence; preoperative systemic inflammatory response syndrome, sepsis, or septic shock; preoperative open wound; preoperative acute renal failure; more than 4 transfusions with packed red blood cells 72 hours prior to surgery; or preoperative dialysis. An MIS was defined as total laparoscopic hysterectomy, laparoscopic supracervical hysterectomy, or laparoscopic-assisted vaginal hysterectomy. Details of study cohort selection are reported in eTables 1 to 5 in the Supplement.
Study Outcomes
Primary outcomes were 30-day major and minor complications. For evaluating the 30-day outcomes before and after the FDA statement, complications following hysterectomies performed from the first quarter of 2013 through the first quarter of 2014 (defined as pre-FDA) were compared with those from the fourth quarter of 2014 through the fourth quarter of 2015 (defined as post-FDA). Hysterectomies performed during the period of transition between the 2 FDA statements (the second through the third quarters of 2014) were excluded. Major complications were defined as unplanned intubation, wound disruption, ventilator use of more than 48 hours, sepsis, septic shock or systemic inflammatory response syndrome, pneumonia, deep incisional surgical site infection, acute renal failure, organ space surgical site infection, progressive renal insufficiency, pulmonary embolism, myocardial infarction, cardiac arrest requiring cardiopulmonary resuscitation, stroke or cerebrovascular accident with neurological deficit, deep vein thrombosis, or thrombophlebitis. Minor complications were defined as any urinary tract infection or superficial surgical site infection. Routes of hysterectomy for benign gynecologic indications were compared between pre-and post-FDA periods.
Statistical Analysis
Two-tailed χ 2 tests and unpaired, 2-tailed t tests were used to compare complication rates, procedure distributions, and patient factors between pre-FDA and post-FDA periods among all women who underwent hysterectomy for benign gynecologic indications as well as in the subset of women with an indication of uterine fibroids. Multivariable logistic regression compared odds of complications before the FDA statement (combining all hysterectomies performed from the first quarter of 2013 through the first quarter of 2014) and after the FDA statement (combining all hysterectomies performed from the fourth quarter of 2014 through the fourth quarter of 2015) after controlling for age, race/ethnicity, body mass index (≥30 vs <30; calculated as the weight in kilograms divided by the height in meters squared), functional status, corticosteroid use for chronic conditions, preoperative platelet count (reference range of 150-450 × 10 , and abdominal, extra-abdominal, upper-abdominal, or other associated procedures (yes vs no). Models, including that for all women with benign gynecologic indications, were also controlled for hysterectomy indication. To verify that increases in the complication rates observed among women with uterine fibroids differed compared with the increases among women with all other benign indications, we performed a secondary analysis among all women with benign conditions that included the interaction between indication (uterine fibroids vs all other benign indications) and period (pre-FDA vs post-FDA) in a multivariable logistic regression model of major complications, controlling for the aforementioned factors. Statistical analysis was performed using SAS, version 9.4 (SAS Institute Inc). All P values were 2-sided and were considered statistically significant at P < .05.
Results
Patient Characteristics
The characteristics of women who underwent hysterectomy for benign indications and for uterine fibroids in the pre-and post-FDA periods are reported in Table 1 . In total, 75 487 women underwent hysterectomy for benign indications, of whom 32 186 (42.6%) were treated in the pre-FDA period and 43 301 (57.4%) were treated in the post-FDA period. The most common indications for hysterectomy were uterine fibroids (33.9%), irregular bleeding (24.6%), and pelvic organ prolapse or urinary incontinence (15.8%). The mean (SD) age was 47.8 (10.7) years, and the mean (SD) body mass index was 30.4 (7.4). Non-Hispanic white women comprised most (59.4%) of the population, followed by African American women (15.1%). In a subgroup of 25 571 women (33.9%) treated for an indication of uterine fibroids, 10 903 (42.6%) underwent hysterectomy in the pre-FDA period and 14 668 (57.4%) in the post-FDA period. For this entire subgroup, the mean (SD) age was 46.9 (7.2) years, and mean (SD) body mass index was 30.6 (7.2). The proportion of African American women was almost double (27.0%) compared with the entire cohort of women treated for a benign indication (15.1%), whereas the proportion of Non-Hispanic white women was lower (44.9%).
Trends in Routes of Hysterectomy From Pre-to Post-FDA Period
Among 75 487 women who underwent hysterectomy for benign gynecologic indications, open abdominal hysterectomy increased from 24.0% during the pre-FDA period to 26.1% during the post-FDA period ( Figure 1 ). The use of MIS decreased from 57.3% during the pre-FDA period to 55.4% during the post-FDA period, while vaginal hysterectomy decreased from 18.7% to 18.4%, respectively. The change in surgical route was significant (P < .001).
Among 25 571 women who underwent hysterectomy for uterine fibroids, the change in route of hysterectomy was more prominent (Figure 2 ). The rate of open abdominal hysterectomy increased from 37.2% during the pre-FDA period to 43.0% during the post-FDA period, the rate of MIS decreased from 56.1% during the pre-FDA period to 49.7% during the post-FDA period, and the rate of vaginal hysterectomy increased from 6.7% during the pre-FDA period to 7.3% during the post-FDA period (P < .001).
Complications Analyzed by Procedure Type
Among 75 487 women who underwent hysterectomy for benign gynecologic indications, 1639 (2.2%) experienced 30-day major complications, and 2752 (3.6%) experienced 30-day minor complications ( Table 2 ). The rates of major complications were significantly higher in women undergoing open abdominal surgery (3.5%) compared with women undergoing MIS (1.7%) or vaginal hysterectomy (1.7%) (P < .001). The minor complication rates were higher in women undergoing vaginal hysterectomy (4.5%), followed by women undergoing open abdominal surgery (4.1%) and women undergoing MIS (3.2%) (P < .001). Similarly, among women who underwent hysterectomy for uterine fibroids, 556 (2.2%) experienced 30-day major complications, and 777 (3.0%) experienced 30-day minor complications ( Table 2 ). The rates of major complications were significantly higher in women undergoing open abdominal surgery (2.8%) compared with women undergoing MIS (1.8%) and women undergoing vaginal hysterectomy (1.8%) (P < .001). Minor complication rates were slightly higher in women undergoing open hysterectomy (3.3%) and women undergoing vaginal hysterectomy (3.2%) than in women undergoing MIS (2.8%), although the difference was not statistically significant (P = .07). Complications Pre-vs Post-FDA Period
Among women who underwent hysterectomy for benign indications, 30-day major and minor complication rates remained relatively stable from the pre-FDA to post-FDA periods ( Figure 3 ). Major complication rates were 2.1% during the pre-FDA period and 2.2% during the post-FDA period (adjusted odds ratio [OR], 1.03; 95% CI, 0.93-1.13; P = .62). Minor complications were 3.6% pre-FDA and 3.7% post-FDA (adjusted OR, 1.00; 95% CI, 0.92-1.08; P = .97). By contrast, among women who underwent hysterectomy for uterine fibroids, 30-day major and minor complication rates significantly increased after the FDA statement ( Figure 3 ). The major complication rate increased from 1.9% during the pre-FDA period to 2.4% during the post-FDA period (adjusted OR, 1.23; 95% CI, 1.04-1.47; P = .02), and the minor complication rate increased from 2.7% during the pre-FDA period to 3.3% during the post-FDA period (adjusted OR, 1.21; 95% CI, 1.04-1.40; P = .01). The full multivariable models for both major and minor complication rates among all women with benign gynecologic indications and also among women with uterine fibroids are reported in eTables 6 to 9 in the Supplement.
Comparisons of individual complication rates during the pre-and post-FDA periods among patients who underwent hysterectomy for benign gynecologic indications and for uterine fibroids are reported in eTable 10 in the Supplement. A model among all women with benign gynecologic indications, including a term for the interaction between indication (uterine fibroids vs nonuterine fibroids) and period (pre-FDA vs post-FDA period), showed that the association of increased complications in the period following the FDA statement was different between women with uterine fibroids and women with nonuterine fibroid indications (P = .009).
Discussion
Our study, using a large nationwide data set, showed that major and minor complication rates among women who underwent . However, except for an increase of blood loss in the later years, other perioperative outcomes remained similar. As recognized by those authors, the generalizability of the study was limited by its single-institution design, and the study was underpowered to detect a small difference. The large sample size in the present study allowed for the detection of a significant 0.5% increase in the rate of major complications among women with an indication of uterine fibroids. Although this increase may appear small, it is larger than the 0.2% risk of unsuspected leiomyosarcoma estimated by the FDA, which was the motivation for the FDA statement and the impetus for using open techniques instead of morcellation. Furthermore, given the large number of women who undergo hysterectomy for uterine fibroids in the United States, a small increase in the rate of complications would translate to a large increase in the number of individual women who experience a major complication. Moreover, a decision-tree analysis including the risk of death from leiomyosarcoma and the differences in morbidity between laparoscopy and laparotomy estimated that the overall mortality would increase if laparoscopic cases were converted to laparotomy cases.
23
Strengths and Limitations
The strengths of the present study include a large sample size from a prospective multicenter database, including centers from across the United States. Moreover, standardized protocols and central auditing ensured reliability of data collection across the participating institutions. The present study has several potential limitations. First, its retrospective design might have introduced bias inherent with such a data set. Second, although the ACS NSQIP is accurate in capturing 30-day complications, it does not follow-up with patients beyond 30 days; therefore, we were unable to assess longterm complications. Third, owing to the lack of data on the use of power morcellation and on the prevalence of abnormal uterine pathology during the pre-and post-FDA periods among women who underwent MIS, we were unable to assess whether the shift in the route of hysterectomy consequent to the FDA statement was associated with a reduction in the prevalence of spreading unexpected malignant neoplasms. However, Wright et al 13 showed that the prevalence of abnormal uterine pathology among woman who underwent MIS with electric power morcellation after the post-FDA period did not change compared with that in the pre-FDA period. Fourth, the increase in the number of participating hospitals between the pre-and post-FDA periods (435 hospitals in 2013, 517 hospitals in 2014, and 603 hospitals in 2015) and the change in the sampling method that occurred for hysterectomy procedures during the study period may have affected our results; however, this limitation cannot be overcome with the available data. Finally, although we could speculate that an increase in the number of complications could have resulted in increased costs and delayed return to work, the lack of data on these variables prevented us from addressing these aspects.
Conclusions
The FDA statement warning against the use of power morcellation was associated with an increased risk in the number of major and minor complications among women undergoing hysterectomy for uterine fibroids. This increased risk corresponded with an abrupt shift in the route of hysterectomy; we believe that many hospitals and payers reduced the use of both forms of morcellation (power and hand), which decreased options for MIS. Although caution is required to avoid morcellation of unexpected uterine malignant neoplasms, our results should be considered by women and clinicians during the process of shared decision making and by medical societies and regulatory bodies when issuing safety communications. Until new studies discover either preoperative techniques to identify patients with sarcomas or alternative intraoperative technology, such as contained power morcellation to remove a large uterus from the abdominal cavity without disseminating tissue, the decision regarding the surgical approach should be guided by the values and informed preferences of the patient. Further research is warranted focusing on the refinement of these alternative techniques of uterine morcellation and on the identification of women who would benefit from MIS.
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Upperabdominal surgery 38100=Splenectomy; total (separate procedure) 38101=Splenectomy; partial (separate procedure) 38102=Splenectomy; total, en bloc for extensive disease, in conjunction with other procedure (List in addition to code for primary procedure) 38115=Repair of ruptured spleen (splenorrhaphy) with or without partial splenectomy 38120=Laparoscopy, surgical, splenectomy 38129=Unlisted laparoscopy procedure, spleen 39501=Repair, laceration of diaphragm, any approach 39541=Repair, diaphragmatic hernia (other than neonatal), traumatic; chronic 39560=Resection, diaphragm; with simple repair (eg, primary suture) 39561=Resection, diaphragm; with complex repair (eg, prosthetic material, local muscle flap) 39599=Unlisted procedure, diaphragm 43195=Esophagoscopy, rigid, transoral; with balloon dilation (less than 30 mm diameter) 43234=Upper gastrointestinal endoscopy, simple primary examination (eg, with small diameter flexible endoscope) (separate procedure) 43235=Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of radical, with regional lymphadenectomy and/or vena caval thrombectomy 50240=Nephrectomy, partial 50280=Excision or unroofing of cyst(s) of kidney 50290=Excision of perinephric cyst 50382=Removal (via snare/capture) and replacement of internally dwelling ureteral stent via percutaneous approach, including radiological supervision and interpretation 50384=Removal (via snare/capture) of internally dwelling ureteral stent via percutaneous approach, including radiological supervision and interpretation 50386=Removal (via snare/capture) of internally dwelling ureteral stent via transurethral approach, without use of cystoscopy, including radiological supervision and interpretation 50387=Removal and replacement of externally accessible transnephric ureteral stent (eg, external/internal stent) requiring fluoroscopic guidance, including radiological supervision and interpretation 50389=Removal of nephrostomy tube, requiring fluoroscopic guidance (eg, with concurrent indwelling ureteral stent) 50393=Introduction of ureteral catheter or stent into ureter through renal pelvis for drainage and/or injection, percutaneous 50394=Injection procedure for pyelography (as nephrostogram, pyelostogram, antegrade pyeloureterograms) through nephrostomy or pyelostomy tube, or indwelling ureteral catheter 50405=Pyeloplasty (Foley Y-pyeloplasty), plastic operation on renal pelvis, with or without plastic operation on ureter, nephropexy, nephrostomy, pyelostomy, or ureteral splinting; complicated (congenital kidney abnormality, secondary pyeloplasty, solitary kidney, calycoplasty) 50541=Laparoscopy, surgical; ablation of renal cysts 50543=Laparoscopy, surgical; partial nephrectomy 50544=Laparoscopy, surgical; pyeloplasty 50545=Laparoscopy, surgical; radical nephrectomy (includes removal of Gerota's fascia and surrounding fatty tissue, removal of regional lymph nodes, and adrenalectomy) 50546=Laparoscopy, surgical; nephrectomy, including partial ureterectomy 50548=Laparoscopy, surgical; nephrectomy with total ureterectomy 50549=Unlisted laparoscopy procedure, renal 50575=Renal endoscopy through nephrotomy or pyelotomy, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service; with endopyelotomy (includes cystoscopy, ureteroscopy, dilation of ureter and ureteral pelvic junction, incision of ureteral pelvic junction and insertion of endopyelotomy stent) 50590=Lithotripsy, extracorporeal shock wave 38572=Laparoscopy, surgical; with bilateral total pelvic lymphadenectomy and peri-aortic lymph node sampling (biopsy), single or multiple 38589=Unlisted laparoscopy procedure, lymphatic system 38700=Suprahyoid lymphadenectomy 38720=Cervical lymphadenectomy (complete) 38740=Axillary lymphadenectomy; superficial 38745=Axillary lymphadenectomy; complete 38746=Thoracic lymphadenectomy by thoracotomy, mediastinal and regional lymphadenectomy (List separately in addition to code for primary procedure) 38747=Abdominal lymphadenectomy, regional, including celiac, gastric, portal, peripancreatic, with or without para-aortic and vena caval nodes (List separately in addition to code for primary procedure) 38760=Inguinofemoral lymphadenectomy, superficial, including Cloquets node (separate procedure) 38765=Inguinofemoral lymphadenectomy, superficial, in continuity with pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes (separate procedure) 38770=Pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes (separate procedure) 38780=Retroperitoneal transabdominal lymphadenectomy, extensive, including pelvic, aortic, and renal nodes (separate procedure) 38790=Injection procedure; lymphangiography 38792=Injection procedure; radioactive tracer for identification of sentinel node 38900=Intraoperative identification (eg, mapping) of sentinel lymph node(s) includes injection of non-radioactive dye, when performed (List separately in addition to code for primary procedure) 38999=Unlisted procedure, hemic or lymphatic system 43611=Excision, local; malignant tumor of stomach 43631=Gastrectomy, partial, distal; with gastroduodenostomy 43632=Gastrectomy, partial, distal; with gastrojejunostomy 43633=Gastrectomy, partial, distal; with Roux-en-Y reconstruction 43634=Gastrectomy, partial, distal; with formation of intestinal pouch 48140=Pancreatectomy, distal subtotal, with or without splenectomy; without pancreaticojejunostomy 48146=Pancreatectomy, distal, near-total with preservation of duodenum (Child-type procedure) 48150=Pancreatectomy, proximal subtotal with total duodenectomy, partial gastrectomy, choledochoenterostomy and gastrojejunostomy (Whipple-type procedure); with pancreatojejunostomy 48152=Pancreatectomy, proximal subtotal with total duodenectomy, partial gastrectomy, choledochoenterostomy and gastrojejunostomy (Whipple-type procedure); without pancreatojejunostomy 48153=Pancreatectomy, proximal subtotal with near-total duodenectomy, choledochoenterostomy and duodenojejunostomy (pylorus-sparing, Whipple-type procedure); with pancreatojejunostomy 48155=Pancreatectomy, total 49220=Staging laparotomy for Hodgkins disease or lymphoma (includes splenectomy, needle or open biopsies of both liver lobes, possibly also removal of abdominal nodes, abdominal node and/or bone marrow biopsies, ovarian repositioning) 49255=Omentectomy, epiploectomy, resection of omentum (separate procedure) 49327=Laparoscopy, surgical; with placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), intra-abdominal, intrapelvic, and/or retroperitoneum, including imaging guidance, if performed, single or multiple (List separately in addition to code for primary procedure) 49411=Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), percutaneous, intra-abdominal, intra-pelvic (except prostate), and/or retroperitoneum, single or multiple 49412=Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), open, intra-abdominal, intrapelvic, and/or retroperitoneum, including image guidance, if performed, single or multiple (List separately in addition to code for primary procedure) 50234=Nephrectomy with total ureterectomy and bladder cuff; through same incision 51570=Cystectomy, complete; (separate procedure) 51575=Cystectomy, complete; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes 51580=Cystectomy, complete, with ureterosigmoidostomy or ureterocutaneous transplantations;51585=Cystectomy, complete, with ureterosigmoidostomy or ureterocutaneous transplantations; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes 51590=Cystectomy, complete, with ureteroileal conduit or sigmoid bladder, including intestine anastomosis; 51595=Cystectomy, complete, with ureteroileal conduit or sigmoid bladder, including intestine anastomosis; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes 51596=Cystectomy, complete, with continent diversion, any open technique, using any segment of small and/or large intestine to construct neobladder 51597=Pelvic exenteration, complete, for vesical, prostatic or urethral malignancy, with removal of bladder and ureteral transplantations, with or without hysterectomy and/or abdominoperineal resection of rectum and colon and colostomy, or any combination thereof 56625=Vulvectomy simple; complete 56630=Vulvectomy, radical, partial; 56631=Vulvectomy, radical, partial; with unilateral inguinofemoral lymphadenectomy 56633=Vulvectomy, radical, complete; 56634=Vulvectomy, radical, complete; with unilateral inguinofemoral lymphadenectomy 56640=Vulvectomy, radical, complete, with inguinofemoral, iliac, and pelvic lymphadenectomy 57107=Vaginectomy, partial removal of vaginal wall; with removal of paravaginal tissue (radical vaginectomy) 57109=Vaginectomy, partial removal of vaginal wall; with removal of paravaginal tissue (radical vaginectomy) with bilateral total pelvic lymphadenectomy and para-aortic lymph node sampling (biopsy) 57110=Vaginectomy, complete removal of vaginal wall; 57111=Vaginectomy, complete removal of vaginal wall; with removal of paravaginal tissue (radical vaginectomy) 57112=Vaginectomy, complete removal of vaginal wall; with removal of paravaginal tissue (radical vaginectomy) with bilateral total pelvic lymphadenectomy and para-aortic lymph node sampling (biopsy) 57156=Insertion of a vaginal radiation afterloading apparatus for clinical brachytherapy 57531=Radical trachelectomy, with bilateral total pelvic lymphadenectomy and para-aortic lymph node sampling biopsy, with or without removal of tube(s), with or without removal of ovary(s) 58200=Total abdominal hysterectomy, including partial vaginectomy, with para-aortic and pelvic lymph node sampling, with or without removal of tube(s), with or without removal of ovary(s) 58210=Radical abdominal hysterectomy, with bilateral total pelvic lymphadenectomy and paraaortic lymph node sampling (biopsy), with or without removal of tube(s), with or without removal of ovary(s) 58240=Pelvic exenteration for gynecologic malignancy, with total abdominal hysterectomy or cervicectomy, with or without removal of tube(s), with or without removal of ovary(s), with removal of bladder and ureteral transplantations, and/or abdominoperineal resection of rectum and colon and colostomy, or any combination thereof 58285=Vaginal hysterectomy, radical (Schauta type operation) 58548=Laparoscopy, surgical, with radical hysterectomy, with bilateral total pelvic lymphadenectomy and para-aortic lymph node sampling (biopsy), with removal of tube(s) and ovary(s), if performed 58943=Oophorectomy, partial or total, unilateral or bilateral; for ovarian, tubal or primary peritoneal malignancy, with para-aortic and pelvic lymph node biopsies, peritoneal washings, peritoneal biopsies, diaphragmatic assessments, with or without salpingectomy(s), with or without omentectomy 58950=Resection (initial) of ovarian, tubal or primary peritoneal malignancy with bilateral salpingooophorectomy and omentectomy; 58951=Resection (initial) of ovarian, tubal or primary peritoneal malignancy with bilateral salpingooophorectomy and omentectomy; with total abdominal hysterectomy, pelvic and limited para-aortic lymphadenectomy 58952=Resection (initial) of ovarian, tubal or primary peritoneal malignancy with bilateral salpingooophorectomy and omentectomy; with radical dissection for debulking (ie, radical excision or destruction, intra-abdominal or retroperitoneal tumors) 58953=Bilateral salpingo-oophorectomy with omentectomy, total abdominal hysterectomy and radical dissection for debulking; 58954=Bilateral salpingo-oophorectomy with omentectomy, total abdominal hysterectomy and radical dissection for debulking; with pelvic lymphadenectomy and limited para-aortic lymphadenectomy 58956=Bilateral salpingo-oophorectomy with total omentectomy, total abdominal hysterectomy for malignancy 58957=Resection (tumor debulking) of recurrent ovarian, tubal, primary peritoneal, uterine malignancy (intra-abdominal, retroperitoneal tumors), with omentectomy, if performed; 58958=Resection (tumor debulking) of recurrent ovarian, tubal, primary peritoneal, uterine malignancy (intra-abdominal, retroperitoneal tumors), with omentectomy, if performed; with pelvic lymphadenectomy and limited para-aortic lymphadenectomy 58960=Laparotomy, for staging or restaging of ovarian, tubal, or primary peritoneal malignancy (second look), with or without omentectomy, peritoneal washing, biopsy of abdominal and pelvic peritoneum, diaphragmatic assessment with pelvic and limited para-aortic lymphadenectomy 60252=Thyroidectomy, total or subtotal for malignancy; with limited neck dissection 77300=Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, only when prescribed by the treating physician 77326=Brachytherapy isodose calculation; simple (calculation made from single plane, one to four sources/ribbon application, remote afterloading brachytherapy, 1 to 8 sources) 77424=Intraoperative radiation treatment delivery, x-ray, single treatment session 77425=Intraoperative radiation treatment delivery, electrons, single treatment session 77469=Intraoperative radiation treatment management 77600=Hyperthermia, externally generated; superficial (ie, heating to a depth of 4 cm or less) 77605=Hyperthermia, externally generated; deep (ie, heating to depths greater than 4 cm) 77620=Hyperthermia generated by intracavitary probe(s) 77786=Remote afterloading high dose rate radionuclide brachytherapy; 2-12 channels 96401=Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic 96445=Chemotherapy administration into peritoneal cavity, requiring and including peritoneocentesis 96446=Chemotherapy administration into the peritoneal cavity via indwelling port or catheter 96549=Unlisted chemotherapy procedure Male 00914=Anesthesia for transurethral procedures (including urethrocystoscopy); transurethral resection of prostate 52649=Laser enucleation of the prostate with morcellation, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, internal urethrotomy and transurethral resection of prostate are included if performed) 53215=Urethrectomy, total, including cystostomy; male 53440=Sling operation for correction of male urinary incontinence (eg, fascia or synthetic) 53442=Removal or revision of sling for male urinary incontinence (eg, fascia or synthetic) 53855=Insertion of a temporary prostatic urethral stent, including urethral measurement 54235=Injection of corpora cavernosa with pharmacologic agent(s) (eg, papaverine, phentolamine) 54300=Plastic operation of penis for straightening of chordee (eg, hypospadias), with or without mobilization of urethra 54326=1-stage distal hypospadias repair (with or without chordee or circumcision); with urethroplasty by local skin flaps and mobilization of urethra 55605=Vesiculotomy; complicated 55812=Prostatectomy, perineal radical; with lymph node biopsy(s) (limited pelvic lymphadenectomy) 55840=Prostatectomy, retropubic radical, with or without nerve sparing; 55866=Laparoscopy, surgical prostatectomy, retropubic radical, including nerve sparing, includes robotic assistance, when performed 55980=Intersex surgery; female to male Pregnancyrelated hysterectomy 58611=Ligation or transection of fallopian tube(s) when done at the time of cesarean delivery or intra-abdominal surgery (not a separate procedure) (List separately in addition to code for primary procedure) 59000=Amniocentesis; diagnostic 59120=Surgical treatment of ectopic pregnancy; tubal or ovarian, requiring salpingectomy and/or oophorectomy, abdominal or vaginal approach 59151=Laparoscopic treatment of ectopic pregnancy; with salpingectomy and/or oophorectomy 59160=Curettage, postpartum 59200=Insertion of cervical dilator (eg, laminaria, prostaglandin) (separate procedure) 59300=Episiotomy or vaginal repair, by other than attending 59350=Hysterorrhaphy of ruptured uterus 59514=Cesarean delivery only; 59525=Subtotal or total hysterectomy after cesarean delivery (List separately in addition to code for primary procedure) 59840=Induced abortion, by dilation and curettage 59870=Uterine evacuation and curettage for hydatidiform mole 
